Tags

Type your tag names separated by a space and hit enter

Should levodopa be used anymore?
Acta Neurol Belg. 2002 Dec; 102(4):163-6.AN

Abstract

Levodopa is the most potent dopaminergic oral drug available in clinical practice. After chronic treatment, many patients with Parkinson's disease develop dyskinesia and motor fluctuations which are difficult to manage. It was hoped that introduction of dopaminergic agonists could diminish these side effects while keeping the same efficacy as levodopa. Prospective clinical data do not support this idea with the present drugs. Levodopa remains the most useful treatment and most clinicians believe that it is wise to associate early on levodopa with one of the dopamine agonists.

Authors+Show Affiliations

Zegers de Beyl D
Service de Neurologie, Hôpital Erasme, U.L.B., Bruxelles, Belgium. diederik.zegers.de.beyl@ulb.ac.be

MeSH

Antiparkinson AgentsBrainDopamineDopamine AgonistsDrug Therapy, CombinationDyskinesia, Drug-InducedHumansLevodopaNeuronal PlasticityParkinson Disease

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12534242

Citation

Zegers de Beyl, Diederik. "Should Levodopa Be Used Anymore?" Acta Neurologica Belgica, vol. 102, no. 4, 2002, pp. 163-6.
Zegers de Beyl D. Should levodopa be used anymore? Acta Neurol Belg. 2002;102(4):163-6.
Zegers de Beyl, D. (2002). Should levodopa be used anymore? Acta Neurologica Belgica, 102(4), 163-6.
Zegers de Beyl D. Should Levodopa Be Used Anymore. Acta Neurol Belg. 2002;102(4):163-6. PubMed PMID: 12534242.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Should levodopa be used anymore? A1 - Zegers de Beyl,Diederik, PY - 2003/1/22/pubmed PY - 2003/3/22/medline PY - 2003/1/22/entrez SP - 163 EP - 6 JF - Acta neurologica Belgica JO - Acta Neurol Belg VL - 102 IS - 4 N2 - Levodopa is the most potent dopaminergic oral drug available in clinical practice. After chronic treatment, many patients with Parkinson's disease develop dyskinesia and motor fluctuations which are difficult to manage. It was hoped that introduction of dopaminergic agonists could diminish these side effects while keeping the same efficacy as levodopa. Prospective clinical data do not support this idea with the present drugs. Levodopa remains the most useful treatment and most clinicians believe that it is wise to associate early on levodopa with one of the dopamine agonists. SN - 0300-9009 UR - https://www.unboundmedicine.com/medline/citation/12534242/Should_levodopa_be_used_anymore DB - PRIME DP - Unbound Medicine ER -